Al­ler­gan scores an FDA OK for a new drug tar­get­ing night-time uri­na­tion

Al­ler­gan has scored a new drug ap­proval. But don’t feel bad if you missed the news late last week. This has been a low-pro­file de­vel­op­ment ef­fort with a long stretch in late-stage de­vel­op­ment.

Al­ler­gan signed a com­mer­cial­iza­tion deal with Seren­i­ty Phar­ma­ceu­ti­cals back in 2010 for SER-120, a nasal spray ther­a­py de­vel­oped to treat a con­di­tion known as noc­tur­nal polyuria, the over­pro­duc­tion of urine at night which can in­ter­rupt sleep with too many trips to the toi­let. The FDA signed off on the ap­proval on Fri­day, set­ting up a launch for this drug as Noc­ti­va.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER